D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
Work
Year: 2023
Type: article
Source: Journal of Thoracic Oncology
Institutions Shanghai Chest Hospital, Zhejiang Cancer Hospital, Zhengzhou University, Second Affiliated Hospital of Zhejiang University, Chongqing Cancer Hospital +16 more
Cites: 33
Cited by: 39
Related to: 10
FWCI: 17.25
Citation percentile (by year/subfield): 99.99
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed